STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

And while much of the attention during earnings season focuses on Big Pharma, several biotech companies, including Nkarta, ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

The stock has been up 30% since Tuesday, and its market cap has now reached more than $1 trillion. SAVA: Cassava Sciences is ...

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...